Corrective press release regarding adverse events information from study AB09004
17/12/2020 – AB Science issues a corrective press release regarding adverse events information from study AB09004 reported on December 16, 2020
17/12/2020 – AB Science issues a corrective press release regarding adverse events information from study AB09004 reported on December 16, 2020
16/12/2020 – AB Science announces that Phase 2B/3 study evaluating masitinib in Alzheimer’s disease met its primary endpoint
04/12/2020 – AB Science announces that confirmatory Phase 3 study AB12005 with masitinib in first line pancreatic cancer with pain met its primary objective to demonstrate increase in survival